Evidence map›Paper›PMID 40370669›Full record

ArticleFrontiers in aging2025

Promising benefits of six-month

Emily Goodbody, Jonathan Maury, Andrea Doolan, Gillian DunnGalvin, Charles Kakilla, Rémi Pradelles, Timothy G Dinan

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04832412 (A Randomised, Double-blind, Placebo-controlled, Parallel Study of the Effect of BrainPhyt on Cognitive Function in Healthy Older Subjects), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04832412 nacompletednot on this map

A Randomised, Double-blind, Placebo-controlled, Parallel Study of the Effect of BrainPhyt on Cognitive Function in Healthy Older Subjects

TypeinterventionalSponsorMicrophytRan2022 to 2023Enrolled66ConditionsHealthy Aging, Dietary Supplement, Fucoxanthin, Cognitive ImpairmentArmsBrainPhyt, 100 % Maltodextrin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emily GoodbodyAtlantia Food Clinical Trials, Heron House Offices, Blackpool, Ireland.
Jonathan MauryMicrophyt, Research and Development Department, Baillargues, France.
Andrea DoolanAtlantia Food Clinical Trials, Heron House Offices, Blackpool, Ireland.
Gillian DunnGalvinAtlantia Food Clinical Trials, Heron House Offices, Blackpool, Ireland.
Charles KakillaAtlantia Food Clinical Trials, Heron House Offices, Blackpool, Ireland.
Rémi PradellesMicrophyt, Research and Development Department, Baillargues, France.
Timothy G DinanAtlantia Food Clinical Trials, Heron House Offices, Blackpool, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Aging is often associated with cognitive decline and memory impairment, with several factors including inflammatory cytokines and oxidative stress markers implicated in this natural process. Microalgae extracts are a natural source of many bioactive compounds that reduce inflammation and oxidative stress, and represent an innovative dietary approach to ameliorate age-related cognitive decline and memory impairment. This proof-of-concept CONSORT-compliant, double-blind, randomized controlled study was conducted to evaluate the effect of daily supplementation of microalgae extract on cognitive function, mood, stress and inflammation of healthy older adults with mild cognitive impairment over a 24-week period. Methods: Sixty-six volunteers with age-associated memory impairment (AAMI; age 55-75 years) were randomly assigned to ingest a placebo (PL, maltodextrin) or 550 mg of Results: There were no between-group differences for the primary outcome (Corsi Block Span Score) or other cognitive function parameters, at either 12 week or 24 weeks. However, within groups, 24 weeks of daily intake of microalgae extract derived from Phaeodactylum tricornutum attenuated age-induced readouts in Stroop task overall reaction time (p = 0.005; Cohen's d = 0.8) and Word recall delayed score (p = 0.010; Cohen's d = 0.5) as compared to baseline week 0, while no significance was reported for these readouts in the placebo group. Similar findings were reported for participants' perceived stress (p = -0.04; Cohen's d = 0.4). There was a significant decrease in blood hs-CRP from 3.9mg/L to 2.1mg/L following 24-weeks of Pt extract supplementation as compared to placebo (p = 0.002; Cohen's d = 0.8), while there was no adverse impact on safety clinical blood tests or reported side effects, with the product deemed safe and tolerable. Discussion: The findings suggest promising benefits of daily intake of microalgae extract on cognitive function and immune markers in older subjects with AAMI. Future research into the preventive role of Pt extract in age-assocaited cognitive decline is warranted. Clinical Trial Registration: Identifier #NCT04832412.

Indexed as

cognitive impairmentdietary supplementfucoxanthinhealthy agingmemorymicroalgaeneuroprotection

Identifiers

PMID40370669
PMCPMC12075122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.